Alvotech (ALVO) Gross Margin (2022 - 2026)
Alvotech's (ALVO) quarterly Gross Margin came in at 4.68% in Q2 2026, down 1747.0% on a YoY basis from 0.28% in Q2 2025, and down 52.98% quarter-over-quarter from 9.95% in Q1 2026.
Powered by 
Analysis
Alvotech (ALVO) Gross Margin (2022 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Gross Margin for 5 consecutive years, with 4.68% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gross Margin fell 1747.0% year-over-year to 4.68%; the trailing twelve-month figure through Jun 2026 stood at 9.88% (up 1939.0% YoY), and the FY2025 full-year result was 14.74%, down 1750.0% from the prior year.
- Gross Margin slipped to 4.68% in Q2 2026 per ALVO's latest filing, from 9.95% in the prior quarter.
- Across five years, Gross Margin topped out at 233.58% in Q2 2022 and bottomed at 1530.09% in Q4 2022.
- Historically, Gross Margin has averaged 189.16% across 5 years, with a median of 1.27% in 2026.
- The widest YoY moves for Gross Margin: up 77895 bps in 2023, down 55416 bps in 2023.
- Over 5 years, Gross Margin stood at 1530.09% in 2022, then jumped by 51 bps to 751.13% in 2023, then jumped by 76 bps to 181.15% in 2024, then jumped by 108 bps to 13.99% in 2025, then sank by 67 bps to 4.68% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 4.68%, 9.95%, and 13.99% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 51.98% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 38.77% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 46.52% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 42.01% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 73.60% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 4.68% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 62.35% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 50.83% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 95.97% |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.68% |
| Mar 31, 2026 | 9.95% |
| Dec 31, 2025 | 13.99% |
| Sep 30, 2025 | -7.22% |
| Jun 30, 2025 | 22.15% |
| Mar 31, 2025 | 40.45% |
| Dec 31, 2024 | -181.15% |
| Sep 30, 2024 | 35.90% |
| Jun 30, 2024 | 15.47% |
| Mar 31, 2024 | -60.56% |
| Dec 31, 2023 | -751.13% |
| Aug 31, 2023 | -198.96% |
| Jun 30, 2023 | -320.58% |
| Dec 31, 2022 | -1,530.09% |
| Aug 31, 2022 | -353.03% |
| Jun 30, 2022 | 233.58% |